Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival
Anna Falanga, Alfonso Vignoli, Erika Diani, Marina MarchettiDivision of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, ItalyAbstract: Patients with cancer are at high risk of developing venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism. Comp...
Main Authors: | Falanga A, Vignoli A, Diani E, Marchetti M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-11-01
|
Series: | Patient Related Outcome Measures |
Online Access: | http://www.dovepress.com/comparative-assessment-of-low-molecular-weight-heparins-in-cancer-from-a8719 |
Similar Items
-
Influence of low molecular weight heparin on cancer patients’ survival
by: V. V. Ptushkin
Published: (2014-07-01) -
Influence of low molecular weight heparin on cancer patients’ survival
by: V. V. Ptushkin
Published: (2014-07-01) -
Assessment of the Safety Profile of Unfractionated Heparin and Low Molecular Weight Heparin
by: Tair-Shin Wang, et al.
Published: (2005) -
Comparison of Pregnancy Outcomes of Low Molecular Weight Heparin with Unfractionated Heparin in the Treatment of Recurrent Abortion Secondary to Antiphospholipid Syndrome
by: M Janghorbani, et al.
Published: (2013-09-01) -
Inhibition of trypsin by heparin and dalteparin, a low molecular weight heparin
by: Bosnić Olivera M., et al.
Published: (2009-01-01)